Skip to main content

Table 2 Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of clinical features

From: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

Variable

 

Mean DFS (months; 95%CI of mean)

P

Mean OS (months; 95%CI of mean)

P

Gender

Male (N = 43)

60.0 (42.3–77.6)

0.2789

83.7 (63.0–105.5)

0.3171

 

Female (N = 42)

84.3 (53.3–115.3)

 

108.5 (77.8–139.1)

 

Age (years)

60 (N = 60)

66.9 (52.1–81.7)

0.3860

98.3 (79.57–117.1)

0.2646

 

> 60 (N = 25)

68.8 (34.0–103.6)

 

93.7 (53.3–134.0)

 

Operation time

Elective (N = 61)

69.4 (46.6–92.1)

0.5463

100.5 (75.8–125.2)

0.6959

 

Non-elective (N = 24)

73.6 (51.3–96.0)

 

85.3 (61.8–108.8)

 

Operative procedure

small intestine resection (N = 78)

68.3 (49.5–87.2)

0.1630

95.5 (74.8–116.2)

0.4290

 

local excision (N = 7)

77.0 (54.7–99.2)

 

76.2 (53.1–99.3)

 

Location

Duodenum (N = 17)

52.3 (31.8–72.7)

0.6391

131.4(95.6–167.1)

0.5399

 

Jejunum (N = 52)

68.6 (53.2–84.0)

 

85.2 (67.1–103.3)

 
 

Ileum (N = 16)

66.8 (24.4–09.2)

 

96.4 (49.2–143.7)

 

Tumor size

2–5 cm (N = 15)

105.1 (79.1–131.)

0.0450

135.7 (101.2–170.2)

0.2413

 

5–10 cm (N = 36)

61.5 (42.5–80.6)

 

78.9 (53.3–104.5)

 
 

> 10 cm (N = 34)

67.6 (38.8–96.5)

 

99.8 (64.9–134.6)

 

Mesenteric involvement

no (anti-mesenteric site) (N = 38)

82.5 (48.7–116.3)

0.7648

108.6 (70.2–146.9)

0.6855

 

yes (mesenteric site) (N = 47)

62.3 (46.0–78.5)

 

89.6 (67.7–111.5)

 

Local invasion

No (N = 65)

82.4 (56.5–108.3)

0.0169

102.9 (76.8–129.0)

0.7962

 

Yes (N = 20)

41.9 (20.6–63.2)

 

90.1(60.7–119.5)

 

Tumor perforation

No (N = 75)

75.7 (55.0–96.5)

0.0485

102.7 (80.8–124.8)

0.0594

 

Yes (N = 10)

30.5 (15.1–45.9)

 

44.3 (29.7–59.0)

 
  1. DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumors